WASHINGTON: The US health advisory panel supports a booster dose of Johnson & Johnson’s Single Vaccine Covid-19 Friday, saying they must be offered at least two months after immunization.
J & J has requested food and medicine for flexibility with the booster, with additional dosage reasons adding important protection as early as two months after initial vaccination – but it might work better if people wait until six months later.
The FDA adviser panel chose unanimously that the booster must be offered without setting a certain time.
Advisers mention the continuous concern that J & J vaccination recipients seem to be less protected than people who have two dosage or modern Pfizer options – and those who get the most single dose a few months ago.
The FDA is not bound by sound but its main decision can help expand the state booster campaign.
The government said the three vaccines A.S.
Continue to offer strong protection against hospitalization and death from Covid-19, and that the priority is getting the first shot that is not vaccinated.
But there was a growing boost to sustain protection against infection “breakthroughs” and a contagious Delta variant of Coronavirus.
The booster dose of the Pfizer vaccine starts last month for high-risk covid-19 people, and the FDA advisory panel has recommended the same approach to modern recipients.
FDA Panel Endorses Booster Shot for Vaccines J & J Covid-19
